

Amniotics to present CogniStem results at international stem cell symposium

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) announces today that the company will present results from the development project CogniStem at Cold Spring Harbor Laboratory (CSHL) Symposium on Quantitative Biology focused on stem cells.

The stem cell symposium is arranged by Cold Spring Harbor Laboratory (CSHL) at Long Island, and will take place May 31 - June 4, 2023.

Amit Saxena, PhD, will present the results of Amniotics mesenchymal stem cell project CogniStem.

About CogniStem™

CogniStem is a neuro specific stem cell product of neonatal origin, derived from full-term amniotic fluid. CogniStem is expected to be efficacious in various central nervous system (CNS) diseases through modulation of the immune response and by supporting the recovery process.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB, e post: certifiedadviser@redeye.se.

Learn more at www.amniotics.com.

Press Release
10 May 2023 15:00:00 CEST



Attachments

[Amniotics to present CogniStem results at international stem cell symposium](#)